JON HALBERT - 17 Jun 2025 Form 3 Insider Report for Caris Life Sciences, Inc. (CAI)

Role
Director
Signature
/s/ J. Russel Denton, Attorney-in-Fact
Issuer symbol
CAI
Transactions as of
17 Jun 2025
Net transactions value
$0
Form type
3
Filing time
17 Jun 2025, 21:30:09 UTC
Previous filing
23 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
HALBERT JON Director C/O CARIS LIFE SCIENCES, INC., 750 W. JOHN CARPENTER FREEWAY, SUITE 800, IRVING /s/ J. Russel Denton, Attorney-in-Fact 17 Jun 2025 0001189394

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CAI Common Stock 116,129 17 Jun 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CAI Series A Preferred Stock 17 Jun 2025 Common Stock 1,250,000 $0.000000 By Ke'Ohana Ventures, LLC F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 16,129 shares of Common Stock underlying restricted stock units which vest in accordance with the applicable grant agreement.
F2 Each share of preferred stock is convertible at the holder's option into 0.25 shares of Common Stock of the Issuer, subject to adjustment in accordance with the certificate of formation, and will automatically convert upon the closing of the initial public offering of the Issuer's Common Stock.
F3 The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.

Remarks:

Exhibit 24 - Power of Attorney.